Compare ATLX & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATLX | PYPD |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | Brazil | Israel |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.3M | 71.7M |
| IPO Year | 2012 | 2014 |
| Metric | ATLX | PYPD |
|---|---|---|
| Price | $2.98 | $4.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $12.00 | ★ $12.25 |
| AVG Volume (30 Days) | ★ 309.1K | 299.5K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $92,491.00 | N/A |
| Revenue This Year | $64,564.67 | N/A |
| Revenue Next Year | $785.59 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.55 | $3.06 |
| 52 Week High | $8.25 | $5.73 |
| Indicator | ATLX | PYPD |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Atlas Lithium Corp is a mineral exploration and development company with lithium projects and exploration properties in other critical and battery minerals, including nickel, rare earth, graphite, and titanium, to power the increased demand for electrification. Its focus is on developing its hard-rock lithium project Minas Gerais Lithium Project, located in Minas Gerais State in Brazil. The company is focused on producing and selling lithium concentrate, a key ingredient for the battery supply chain.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.